|
26 Nov 2020 |
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
|
|
26 Nov 2020 |
COVAXX Announces $2.8 Billion in Advance Purchase Commitments to Deliver More Than 140 Million Vaccine Doses to Emerging Countries
|
|
24 Nov 2020 |
City of Hope Initiates Phase 1 Clinical Trial to Test Its First SARS-CoV-2 Investigational Vaccine
|
|
24 Nov 2020 |
GSK starts phase 3 study of RSV maternal candidate vaccine
|
|
23 Nov 2020 |
INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)
|
|
23 Nov 2020 |
Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine
|
|
23 Nov 2020 |
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency
|
|
23 Nov 2020 |
Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency
|
|
23 Nov 2020 |
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
|
|
23 Nov 2020 |
AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
|
|
20 Nov 2020 |
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
|
|
19 Nov 2020 |
European Commission approves Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
|
|
19 Nov 2020 |
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection
|
|
19 Nov 2020 |
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
|
|
18 Nov 2020 |
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
|
|
18 Nov 2020 |
Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases
|
|
17 Nov 2020 |
AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
|
|
17 Nov 2020 |
European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)
|
|
17 Nov 2020 |
Tonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates
|
|
17 Nov 2020 |
INOVIO announces initiation of Phase 2 segment of Phase 2/3 clinical trial for COVID-19 DNA vaccine candidate INO-4800
|
|
17 Nov 2020 |
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate
|
|
16 Nov 2020 |
Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures
|
|
16 Nov 2020 |
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
|
|
16 Nov 2020 |
Intravacc publishes positive phase I Shigella conjugate vaccine data
|
|
13 Nov 2020 |
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
|
